Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 6—June 2019
CME ACTIVITY - Synopsis

Epidemiologic and Clinical Features of Lassa Fever Outbreak in Nigeria, January 1–May 6, 2018

Elsie A. Ilori1, Yuki Furuse1, Oladipupo B. Ipadeola1, Chioma C. Dan-Nwafor1, Anwar Abubakar, Oboma E. Womi-Eteng, Ephraim Ogbaini-Emovon, Sylvanus Okogbenin, Uche Unigwe, Emeka Ogah, Olufemi Ayodeji, Chukwuyem Abejegah, Ahmed A. Liasu, Emmanuel O. Musa, Solomon F. Woldetsadik, Clement L.P. Lasuba, Wondimagegnehu Alemu, Chikwe IhekweazuComments to Author , and Nigeria Lassa Fever National Response Team
Author affiliations: Nigeria Centre for Disease Control, Abuja, Nigeria (E.A. Ilori, O.B. Ipadeola, C.C. Dan-Nwafor, A. Abubakar, O.E. Womi-Eteng, C. Ihekweazu); Kyoto University, Kyoto, Japan (Y. Furuse); World Health Organization, Abuja (Y. Furuse, E.O. Musa, S.F. Woldetsadik, C.L.P. Lasuba, W. Alemu); US Centers for Disease Control and Prevention, Abuja (O.B. Ipadeola); African Field Epidemiology Network, Abuja (C.C. Dan-Nwafor); Irrua Specialist Teaching Hospital, Irrua, Nigeria (E. Ogbaini-Emovon, S. Okogbenin); Federal Teaching Hospital, Abakaliki, Nigeria (U. Unigwe, E. Ogah); Federal Medical Centre, Owo, Nigeria (O. Ayodeji, C. Abejegah, A.A. Liasu)

Main Article

Figure 2

Exposure history and case-fatality rate among patients with laboratory-confirmed Lassa fever cases, Nigeria, January 1–May 6, 2018. A) Proportion of persons reporting Lassa fever exposure risks for all case-patients, HCWs, and non–HCWs. To assess differences in exposure risks between HCWs and non–HCWs, p values were calculated by using the χ2 test and adjusted by the Bonferroni correction. B) The case-fatality rate for case-patients who did or did not receive ribavirin. C) An investigation of th

Figure 2. Exposure history and case-fatality rate among patients with laboratory-confirmed Lassa fever cases, Nigeria, January 1–May 6, 2018. A) Proportion of persons reporting Lassa fever exposure risks for all case-patients, HCWs, and non–HCWs. To assess differences in exposure risks between HCWs and non–HCWs, p values were calculated by using the χ2 test and adjusted by the Bonferroni correction. B) The case-fatality rate for case-patients who did or did not receive ribavirin. C) An investigation of the case-fatality rate in patients who survived >7 days after symptom onset. For panels B and C, p values were calculated by using binomial logistic regression analysis adjusted for age and sex and applying the Bonferroni correction. HCW, healthcare worker.

Main Article

1These first authors contributed equally to this article.

2Other members of the Nigeria Lassa Fever National Response Team are listed at the end of this article.

Page created: May 19, 2019
Page updated: May 19, 2019
Page reviewed: May 19, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external